Kane Biotech Introduces Investor Relations Professional

WINNIPEG, MANITOBA -- (MARKET WIRE) -- 01/08/07 -- Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development of products that prevent and disperse bacterial biofilms, is pleased to introduce Ms. Sandra Benson as Manager, Investor Relations. Ms Benson will continue to enhance the Company's corporate image and relationship with investors and business partners.

"With our recent announcements of lead products for coating urinary and central venous catheters and our growing pipeline of antimicrobial products that prevent and disperse bacterial biofilms, we remain committed to building our business and maximizing value to our shareholders", stated Mr. Gord Froehlich, President of Kane Biotech Inc. "In light of that commitment, we are pleased to have Ms. Benson join the Kane team to provide dedicated investor relations management for the Company."

Ms. Benson will actively focus on providing a comprehensive investor relations strategy for Kane Biotech, concentrating on strengthening communications with current and potential shareholders, while increasing market awareness throughout the financial and investment community and the trade media.

Previous to joining Kane, Ms. Benson gained valuable experience within the financial services industry working for BMO Financial Group and most recently, Investors Group Inc. She holds a Bachelor of Arts in Economics from the University of Manitoba.

"I look forward to representing Kane and building awareness of the Company's developments." stated Ms. Benson.

Kane Biotech has entered into a 12 month renewable agreement with Genesys Venture Inc. (GVI) for the provision of enhanced investor relations services. Ms. Benson is an employee of GVI and will provide services to Kane Biotech through this agreement.

GVI provides management services to emerging health and biotechnology ventures through an enhanced business incubator model. It employs a team of experienced scientific and business personnel who provide strategic direction to the research, business development and investor relations activities of client companies to ensure their success.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse bacterial biofilms. Biofilms develop when bacteria, and other microorganisms, form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay. An estimated 80% of all human infections involve biofilms.

Kane Biotech Inc. uses a patent protected technology based on molecular mechanisms of biofilm formation and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that this technology has potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.

Certain information contained in this press release may be forward-looking and is subject to risks and uncertainties. Although the Company believes that the expectations contained herein are reasonable, it can give no assurances such forward-looking statements will prove correct. Information is provided from sources deemed to be reliable.

The TSX Venture Exchange has neither approved nor disapproved the contents of this press release.

Contacts:
Kane Biotech Inc.
Sandra Benson
Manager, Investor Relations
(204) 478-5602
(204) 453-1314 (FAX)
Email: sbenson@kanebiotech.com
Website: www.kanebiotech.com

Released January 8, 2007